The absence of proven vaccines to address the 2026 outbreaks of hantavirus and Ebola virus disease caused by Bundibugyo virus (species Orthoebolavirus bundibugyoense) underscores the essential role of the Coalition for Epidemic Preparedness Innovations (CEPI) in protecting everyone’s health. On June 1, 2026, CEPI announced it would invest up to US$61·8 million to rapidly advance testing and production of three Bundibugyo vaccine candidates.1,2 CEPI pools public and philanthropic funds internationally to advance vaccine development for epidemics and pandemics in a way meant to benefit all countries.
Source: [Comment] How CEPI can enhance global vaccine equity and transparency